Montag & Caldwell LLC cut its holdings in Edwards Lifesciences Corp (NYSE:EW) by 2.0% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 203,675 shares of the medical research company’s stock after selling 4,067 shares during the period. Edwards Lifesciences accounts for 1.9% of Montag & Caldwell LLC’s portfolio, making the stock its 28th largest holding. Montag & Caldwell LLC’s holdings in Edwards Lifesciences were worth $37,627,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in EW. Dimensional Fund Advisors LP lifted its position in shares of Edwards Lifesciences by 3.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 601,150 shares of the medical research company’s stock worth $92,071,000 after buying an additional 22,354 shares during the period. Geode Capital Management LLC raised its position in Edwards Lifesciences by 7.4% in the 4th quarter. Geode Capital Management LLC now owns 2,942,494 shares of the medical research company’s stock valued at $449,976,000 after purchasing an additional 202,248 shares during the last quarter. Mercer Global Advisors Inc. ADV bought a new position in Edwards Lifesciences in the 1st quarter valued at $843,000. First Manhattan Co. raised its position in Edwards Lifesciences by 630.3% in the 1st quarter. First Manhattan Co. now owns 2,337 shares of the medical research company’s stock valued at $447,000 after purchasing an additional 2,017 shares during the last quarter. Finally, Virtu Financial LLC bought a new position in Edwards Lifesciences in the 1st quarter valued at $296,000. Institutional investors and hedge funds own 82.43% of the company’s stock.

Shares of EW stock traded up $2.57 on Thursday, reaching $216.08. 30,414 shares of the stock were exchanged, compared to its average volume of 1,186,828. The company has a market capitalization of $44.90 billion, a PE ratio of 45.93, a PEG ratio of 2.72 and a beta of 0.87. Edwards Lifesciences Corp has a one year low of $134.53 and a one year high of $219.71. The company has a current ratio of 3.38, a quick ratio of 2.48 and a debt-to-equity ratio of 0.18. The firm’s 50 day moving average price is $200.64.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Tuesday, July 23rd. The medical research company reported $1.38 earnings per share for the quarter, topping analysts’ consensus estimates of $1.33 by $0.05. The company had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.04 billion. Edwards Lifesciences had a return on equity of 31.25% and a net margin of 18.29%. The firm’s quarterly revenue was up 15.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.24 earnings per share. As a group, analysts anticipate that Edwards Lifesciences Corp will post 5.34 earnings per share for the current year.

In related news, VP Donald E. Bobo, Jr. sold 5,369 shares of Edwards Lifesciences stock in a transaction on Friday, August 9th. The stock was sold at an average price of $216.26, for a total transaction of $1,161,099.94. Following the completion of the sale, the vice president now directly owns 26,082 shares of the company’s stock, valued at $5,640,493.32. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Michael A. Mussallem sold 22,850 shares of Edwards Lifesciences stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $184.27, for a total value of $4,210,569.50. Following the sale, the chief executive officer now directly owns 95,770 shares of the company’s stock, valued at $17,647,537.90. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 142,948 shares of company stock valued at $27,936,332. 1.63% of the stock is currently owned by corporate insiders.

Several equities analysts have issued reports on the company. Canaccord Genuity lifted their price objective on Edwards Lifesciences from $215.00 to $250.00 and gave the company a “buy” rating in a research report on Wednesday, July 24th. Raymond James lifted their price objective on Edwards Lifesciences from $200.00 to $232.00 and gave the company an “outperform” rating in a research report on Wednesday, July 24th. Jefferies Financial Group lifted their price objective on Edwards Lifesciences from $210.00 to $245.00 and gave the company a “buy” rating in a research report on Wednesday, July 24th. BTIG Research reiterated a “hold” rating on shares of Edwards Lifesciences in a research report on Thursday, July 25th. Finally, Wells Fargo & Co lifted their price objective on Edwards Lifesciences from $207.00 to $220.00 and gave the company an “outperform” rating in a research report on Wednesday, July 24th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and fourteen have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $204.74.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Featured Article: What does it mean to hold a stock in street name?

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.